Zealand Pharma Stock Drops Amid Analyst Coverage
What happened
Zealand Pharma A/S is a Denmark-based biotechnology company specializing in peptide-based medicines. On September 24, 2026, the company's stock experienced a gap down prior to trading. The stock had previously closed at $46.3750 but opened at $43.1050, with the last traded price at $43.1050.
From tickerreport.com
Why it matters
As a publicly traded biotech company, the stock price movement directly impacts its market valuation and funding potential. The company has received various analyst ratings, leading to a consensus rating of 'Hold.'
From tickerreport.com
Who's involved
- Zealand PharmaDenmark-based biotechnology company focused on peptide-based medicines
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Zealand PharmaSpeculative
The company could face challenges related to market funding and investor confidence due to the stock price movement.
Keep exploring
The entities involved
-
Zealand Pharma
Danish biotechnology research company
Nothing else this week.
-
Denmark
country in Northern Europe and North America
Related events
- Both Zealand Pharma and Cartesian Therapeutics are clinical-stage biotech firms.
- A company based in Denmark is conducting clinical trials.
- Ascendis Pharma is headquartered in Copenhagen, Denmark, and the ESPE 2026 conference is being held in Marseille.
- Genmab, a Danish biotechnology company, granted stock units and warrants via its Board of Directors on September 1, 2026.